Development of drugs for rare diseases
By working with our partners, we are able to tackle new projects concerning drug development for rare diseases. For this, we profit from the medicinal knowledge, over the last 2000 years, with more than 35,000 phyto-pharma ingredients available. We combine this existing knowledge with rare diseases and with the expertise of our competence group of scientists and consultants with experience in research, therapy, patient organizations, social network, as well as, innovation and strategy advice. This is the competentce procedure that we follow to secure projects and research. Thanks to this cooperation, the Foundation is supported for future research. Licensing additional partners will provide the best possibilities to increase our knowledge for a multitude of diseases. We are convinced that this will be successful. Our first two projects are currently on line and help to bridge an important gap in the treatment of rare disease. Read more about our projects.
Development of the competence network
The Foundation’s competence network is possible due to the engagement of Universities, patient organizations, research institutions, social networks and organizations, and other pharmaceutical companies. Together they render pioneer work in the field of rare diseases. These partners bring all their know-how from different areas, providing an important contribution to the Foundation in terms of networking, financial engagement and sponsorship. Find out more about our partners and sponsors.
Active integration and mobilization of patients
We motivate people affected by rare disease, to be engaged with patients projects. We promote a network and interchange for patients and their relatives in order to give force and weight to their voice. In doing so, we increase the knowledge about rare diseases and raise awareness in society.
Bridging knowledge to ideas
We improve knowledge and implement new projecs by building upon our competence network. This is possible due to the interaction with partners (universities, patient organizations, research institutions, social networks and pharmaceutical companies)and public awareness about rare diseases. We combine this knowledge and use it to implement new projects.
